Ironwood Pharma (IRWD) Tops Q3 EPS by 6c; Trims Cash Burn Outlook

Ironwood Pharma (NASDAQ: IRWD) reported Q3 EPS of ($0.18), $0.06 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $66.1 million versus the consensus estimate of $60.01 million.

Ironwood now expects to use less than $50 million in cash for operations in 2016, down from previous guidance of less than $70 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge